SCHEDULE: Vanguard Discloses 5.97% Stake in Core Scientific

Vanguard Portfolio Management has reported beneficial ownership of 18,843,184 shares, representing 5.97% of Core Scientific Inc.'s common stock, as of March 31, 2026.

Summary

• Vanguard Portfolio Management, along with its affiliates Vanguard Fiduciary Trust Company and Vanguard Global Advisers, LLC, has disclosed a beneficial ownership stake in Core Scientific Inc.
• The filing indicates beneficial ownership of 18,843,184 shares of Core Scientific's common stock.
• This holding represents 5.97% of the total class of securities.
• The reporting date for this ownership is March 31, 2026.
• Vanguard Portfolio Management exercises sole dispositive power over 18,843,184 shares and sole voting power over 228,648 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It is a routine disclosure of institutional ownership and does not provide new operational or financial information about Core Scientific itself, thus having no direct positive or negative sentiment impact on its own.

Positives

• Vanguard, a major institutional investor, has taken a significant stake in Core Scientific, which could be interpreted as a vote of confidence in the company's future prospects.
• The disclosure indicates that Vanguard manages funds and accounts that hold these shares, suggesting a broad base of underlying investors benefiting from this holding.

Negatives

• The filing does not contain any negative financial results or operational issues for Core Scientific; it is purely an ownership disclosure.

Risks

• The filing does not explicitly mention any risks associated with Core Scientific's business operations or financial health. The risks are inherent to any investment in a publicly traded company, such as market volatility and company-specific performance.

Future Outlook

The filing is a Schedule 13G, which reports beneficial ownership and does not contain forward-looking statements or guidance from Core Scientific Inc. regarding its future performance.

Management Comments

• "In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Portfolio Management LLC and the following affiliates of Vanguard Portfolio Management LLC or business divisions of such affiliates: Vanguard Fiduciary Trust Company and Vanguard Global Advisers, LLC."
• "This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Portfolio Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power."
• "This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Portfolio Management LLC, or business divisions of such subsidiaries whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that a Schedule 13G filing by a major asset manager like Vanguard indicates a significant institutional investment in the company. This type of filing is common for passive investors who acquire more than 5% of a company's stock but do not intend to influence control. For Core Scientific, a company in the digital asset infrastructure sector, such investment from a large entity can signal growing institutional interest in the industry.

Stakeholder Impact

• Shareholders: The filing confirms Vanguard as a significant institutional shareholder, which can add stability and potentially attract further institutional interest. However, it does not directly impact current share price or dividends.
• Creditors: No direct impact as this is an ownership disclosure, not a financial health report.
• Employees: No direct impact mentioned in the filing.
• Customers/Suppliers: No direct impact mentioned in the filing.

Next Steps

• Vanguard will continue to hold or manage its stake in Core Scientific according to its investment strategies.
• Core Scientific Inc. will continue its business operations, with Vanguard as a significant passive shareholder.

Key Dates

Keywords

Core Scientific, Vanguard, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, SEC Filing, Vanguard Portfolio Management, Vanguard Fiduciary Trust Company, Vanguard Global Advisers